Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine for protein expression restoration, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a presentation on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT).

The presentation will be accessible through a live audio webcast on the Investors & News section of Stoke's website. Interested parties can access the webcast through the company's investor relations portal, and a replay will remain available for 30 days following the presentation.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT).

A live audio webcast of the presentation will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/ and can be accessed by following this Link. A replay of the webcast will be available for 30 days following the presentation.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108980972/en/

Stoke Media & Investor Contacts:

Dawn Kalmar

Chief Communications Officer

dkalmar@stoketherapeutics.com

781-383-8417

Doug Snow

Director, Communications & Investor Relations

IR@stoketherapeutics.com

508-642-6485

Source: Stoke Therapeutics, Inc.

FAQ

When is Stoke Therapeutics (STOK) presenting at the 2025 J.P. Morgan Healthcare Conference?

Stoke Therapeutics will present on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT).

How long will the STOK J.P. Morgan Healthcare Conference presentation replay be available?

The webcast replay will be available for 30 days following the presentation.

Where can investors watch Stoke Therapeutics' (STOK) J.P. Morgan Healthcare Conference presentation?

Investors can watch the live audio webcast through the Investors & News section of Stoke's website at investor.stoketherapeutics.com.

What is the focus of Stoke Therapeutics' (STOK) research and development?

Stoke Therapeutics focuses on restoring protein expression by harnessing the body's potential with RNA medicine.